Home / Going-concern warnings / Sensei Biotherapeutics, Inc.

3/5Sensei Biotherapeutics, Inc. (SNSE): Going-concern doubt

Filed 2025-11-14 路 Form 10-Q 路 Accession 0001193125-25-281590 nano

Market data

Price before filing: $9.02 (2025-11-13 close, split/dividend-adjusted)
Market cap at flag: $10.1M (2025-11-14) 路 Latest: $43.2M (2026-07-13)

What happened next

WindowSNSESPYvs SPY
30 days-12.5%+1.3%-13.8%2025-12-15
90 days+0.8%+1.7%-0.9%2026-02-12
180 days+133.7%+11.1%+122.6%2026-05-13

Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.

Insider trading around this filing

90 days before the flag: no open-market insider sales or purchases reported.
30 days after: 2 insiders sold $575K (16 sales)

DateInsiderTypeSharesPriceValue10b5-1 planSource
2025-11-14: red flag filed
2025-12-04Cambrian BioPharma Inc
10% owner
Sale5,000$9.06$45KnoForm 4
2025-12-04Peyer James
10% owner
Sale5,000$9.06$45KnoForm 4
2025-12-05Cambrian BioPharma Inc
10% owner
Sale14,508$11.40$165KnoForm 4
2025-12-05Cambrian BioPharma Inc
10% owner
Sale1,745$12.29$21KnoForm 4
2025-12-05Cambrian BioPharma Inc
10% owner
Sale42$13.16$553noForm 4
2025-12-05Peyer James
10% owner
Sale14,508$11.40$165KnoForm 4
2025-12-05Peyer James
10% owner
Sale1,745$12.29$21KnoForm 4
2025-12-05Peyer James
10% owner
Sale42$13.16$553noForm 4
2025-12-08Peyer James
10% owner
Sale3,105$8.59$27KnoForm 4
2025-12-09Cambrian BioPharma Inc
10% owner
Sale3,105$8.59$27KnoForm 4
2025-12-09Cambrian BioPharma Inc
10% owner
Sale2,666$7.95$21KnoForm 4
2025-12-09Cambrian BioPharma Inc
10% owner
Sale395$8.04$3KnoForm 4
2025-12-09Cambrian BioPharma Inc
10% owner
Sale446$7.92$4KnoForm 4
2025-12-09Peyer James
10% owner
Sale2,666$7.95$21KnoForm 4
2025-12-09Peyer James
10% owner
Sale395$8.04$3KnoForm 4
2025-12-09Peyer James
10% owner
Sale446$7.92$4KnoForm 4

Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-08-16 to 2025-12-14. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.

Verified excerpt

"Based on the Company's available cash, cash equivalents and marketable securities and current operating plans excluding any financing, and consideration of the above factors, it is not probable that the Company will have sufficient cash and cash equivalents to fund its operating expenses and capital requirements within one year from the issuance of these condensed consolidated financial statements, and therefore,..."

Quoted from the filing. Source

What this means

The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.

Source: management disclosure in Form 10-Q (period 2025-09-30)

Why this score: quarterly (unaudited) disclosure

Read the original filing on SEC.gov →

Not investment advice. Automated summary; verify against the filing.

Get the weekly "Red Flags" newsletter

The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.

Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.

Form not showing? Subscribe on beehiiv →

Newsletter delivered by beehiiv. See our privacy policy.